Foamix Pharmaceuticals Ltd Logo Image

Foamix Pharmaceuticals Ltd

Foamix Pharmaceuticals Ltd has reached its limit for report views.

Please check back to see if Foamix Pharmaceuticals Ltd has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

Most Recent Annual Report

2016 Annual Report

Foamix Pharmaceuticals Ltd

Foamix Pharmaceuticals Ltd does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

  • Foamix Pharmaceuticals Ltd
  • Foamix Pharmaceuticals Ltd

About Foamix Pharmaceuticals Ltd

11-50 Employees
Based in Rehovot, Israel

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for the treatment of acne, impetigo, and other skin conditions in the United States, Germany, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus.

Ticker:
FOMX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol